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Clinical PerspectiveWhat Is New?Using data from the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) trial, we demonstrated that patients with and without diabetes mellitus have similar clinical presentations.Patients with diabetes mellitus are more likely to be referred for stress imaging tests than nonimaging tests and, specifically, nuclear tests.Patients with and without diabetes mellitus have a similar pretest likelihood of obstructive coronary artery disease based on the Diamond‐Forrester and Coronary Artery Surgery Study scores.In contrast, physicians perceive that patients with diabetes mellitus have a higher pretest likelihood of obstructive coronary artery disease, an assessment supported by an increased likelihood of a positive noninvasive test.What Are the Clinical Implications?The presence of diabetes mellitus influences the diagnostic pathway and results of noninvasive test among low‐risk patients with symptoms suggestive of coronary artery disease.For patients with diabetes mellitus and stable chest pain symptoms, additional strategies to assess for coronary artery disease, including optimal test selection and risk stratification, need to be evaluated.

Introduction {#jah32674-sec-0009}
============

In the United States, over 29 million adults have a diagnosis of diabetes mellitus, and the prevalence will grow in the next few decades.[1](#jah32674-bib-0001){ref-type="ref"} Although cardiovascular disease is one of the leading causes of death and disability among patients with diabetes mellitus,[2](#jah32674-bib-0002){ref-type="ref"}, [3](#jah32674-bib-0003){ref-type="ref"} identifying these patients remains a challenge---particularly among the majority of patients who do not present with acute coronary syndromes.[4](#jah32674-bib-0004){ref-type="ref"}, [5](#jah32674-bib-0005){ref-type="ref"}, [6](#jah32674-bib-0006){ref-type="ref"}, [7](#jah32674-bib-0007){ref-type="ref"} Among stable symptomatic outpatients with diabetes mellitus, there are few data regarding patient demographic and presentation profiles, physician practice with respect to noninvasive test (NIT) selection, rates of NIT positivity, and predictors of NIT results, information which is required to improve the value of healthcare services delivered to this at‐risk group. We analyzed these questions using contemporary data from the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain), a randomized trial of diagnostic evaluation strategy in 10 003 stable outpatients with symptoms suggestive of coronary artery disease (CAD).[8](#jah32674-bib-0008){ref-type="ref"}, [9](#jah32674-bib-0009){ref-type="ref"} We compared symptomatic patients with and without diabetes mellitus to assess: (1) demographic and risk factor profiles; (2) clinical presentation; (3) physician preference for functional stress test modality; (4) NIT results; and (5) predictors of NIT positivity and the ability of these predictors to discriminate for a positive NIT result.

Methods {#jah32674-sec-0010}
=======

Patient Population {#jah32674-sec-0011}
------------------

The methods and results of the PROMISE trial have been previously described.[8](#jah32674-bib-0008){ref-type="ref"}, [9](#jah32674-bib-0009){ref-type="ref"} In brief, 10 003 symptomatic stable outpatients without a history of CAD were randomized to initial anatomical testing with 64‐slice multi‐detector coronary computed tomographic angiography or functional testing (exercise ECG, stress nuclear imaging, or stress echocardiogram). There were 2144 patients with diabetes mellitus (21%) and 7858 without diabetes mellitus (79%); diabetic status of 1 patient was unknown. Before randomization, the local providers were required to prespecify the functional test that the patient would undergo should the patient be randomized to that arm. Local or central institutional review boards approved the study at the coordinating centers and each of the 193 enrolling sites in North America. Patients provided written informed consent before randomization.

Baseline Variable and Data Collection {#jah32674-sec-0012}
-------------------------------------

Baseline patient data on demographics, risk factor profiles, ECG findings, symptoms, and CAD risk estimates were collected for all patients. Data from risk assessment scores (2008 Framingham score,[10](#jah32674-bib-0010){ref-type="ref"} the 2013 Atherosclerotic Cardiovascular Disease \[ASCVD\] score,[11](#jah32674-bib-0011){ref-type="ref"} and the 2012 combined Diamond‐Forrester and CASS \[Coronary Artery Surgery Study\] score[12](#jah32674-bib-0012){ref-type="ref"}) were calculated for the entire population. In calculating the Framingham and ASCVD scores, the single imputation method was used to replace missing values of cholesterol and high‐density lipoprotein with the mean of nonmissing observations, as described previously.[13](#jah32674-bib-0013){ref-type="ref"}, [14](#jah32674-bib-0014){ref-type="ref"} In particular, the imputation of cholesterol was stratified by history of dyslipidemia and statin use at baseline, and the imputation of high‐density lipoprotein was stratified by sex. Test results according to site interpretation were recorded for the first NIT performed. Overall, there were 8966 patients with an interpretable NIT (1908 \[21%\] with diabetes mellitus and 7058 \[79%\] without diabetes mellitus). On the coronary computed tomography angiography scan, positivity was defined as ≥70% major epicardial stenosis or ≥50% left main stenosis. Positivity on an exercise ECG was defined as ST‐segment changes consistent with ischemia during stress being detected or if the test was terminated early (\<3 minutes) because of reproduction of symptoms, arrhythmia, and/or hypotension. Positivity on stress nuclear and stress echocardiography tests was defined as inducible ischemia in at least 1 coronary territory (septal/anterior/apical; inferior/posterior; or lateral).

Statistical Analysis {#jah32674-sec-0013}
--------------------

Baseline characteristics were summarized using median (25th, 75th percentiles) for continuous variables and frequencies/percentages for categorical variables.

To determine whether the likelihood of a physician preferring an imaging functional test over a nonimaging functional test differed between diabetic and nondiabetic patients, a multivariable generalized linear mixed model was fit using a generalized logit‐link function. To determine whether this relationship persisted after accounting for demographic information, the model was adjusted for age, sex, and testing site (as a random effect). A similar approach was utilized to assess whether the likelihood of a physician preferring stress nuclear over stress echocardiography differed between diabetic and nondiabetic patients who received an imaging stress test.

To assess whether the likelihood of having a positive NIT differed between patients with and without diabetes mellitus, a logistic regression model was fit. Adjusted analyses controlled for randomized testing modality, age, and sex.

To determine the factors most predictive of a positive NIT in patients with or without diabetes mellitus separately, multivariable logistic regression models were fit using step‐wise variable selection with liberal entry and exit criteria (entry, *P*\<0.1; exit, *P*\>0.2) to select the best subset of predictors from among a comprehensive set of clinically guided candidate predictors. The following candidate predictors were considered for patients with or without diabetes mellitus: age; race; body mass index; hypertension; sex; metabolic syndrome; dyslipidemia; history of carotid, peripheral vascular, or cerebrovascular disease; history of heart failure; smoking (ever, never); family history of premature CAD; depression; physical activity; CAD equivalent; Framingham Risk Score (2008); ASCVD risk prediction; Diamond‐Forrester; Combined Diamond‐Forrester and CASS; Diamond‐Forrester (2011); presenting symptom; and chest pain characterization. In each case, age, sex, and chest pain characterization were forced into the final selected model. Calibration of the final models selected was assessed using the Hosmer--Lemeshow goodness‐of‐fit test, and discrimination was assessed using the area under a receiver operating characteristic curve.

All statistical calculations were conducted using SAS (version 9.4; SAS Institute Inc, Cary, NC).

Results {#jah32674-sec-0014}
=======

Baseline Demographics and Primary Presenting Symptoms {#jah32674-sec-0015}
-----------------------------------------------------

Patient distribution and study design are shown in Figure [S1](#jah32674-sup-0001){ref-type="supplementary-material"}. Among all enrolled patients (n=10 002), there were no clinically significant differences between patients with diabetes mellitus (n=2144) and those without diabetes mellitus (n=7858) with regard to age (median 61 versus 60 years) or sex (female 54% versus 52%). However, patients with diabetes mellitus were more likely to have hypertension (80% versus 61%), dyslipidemia (77% versus 65%), depression (24% versus 20%), and a sedentary lifestyle (57% versus 47%; Table [1](#jah32674-tbl-0001){ref-type="table-wrap"}). Patients with diabetes mellitus had a higher body mass index (33 versus 29 kg/m^2^) and were more likely to have metabolic syndrome (85% versus 25%; Table [1](#jah32674-tbl-0001){ref-type="table-wrap"}). Patients with diabetes mellitus, compared with those without, were more likely to be on aspirin, statin, beta‐blocker, angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker, or diuretics (Table [1](#jah32674-tbl-0001){ref-type="table-wrap"}). At baseline, 74% of patients with diabetes mellitus were on oral hypoglycemics, and 23% were on insulin, with the remainder treated with diet alone.

###### 

Patient Characteristics

  Characteristic                                                               Diabetes Mellitus (N=2144)   No Diabetes Mellitus (N=7858)
  ---------------------------------------------------------------------------- ---------------------------- -------------------------------
  Demographics                                                                                              
  Age, y                                                                                                    
  Median (25th, 75th)                                                          60.6 (55.0, 66.3)            59.8 (54.3, 65.8)
  Female sex, n/N (%)                                                          1151/2144 (53.7)             4119/7858 (52.4)
  Race, n/N (%)                                                                                             
  Multiracial                                                                  19/2113 (0.9)                76/7802 (1.0)
  White                                                                        1629/2113 (77.1)             6741/7802 (86.4)
  Black                                                                        354/2113 (16.8)              742/7802 (9.5)
  Asian                                                                        75/2113 (3.5)                178/7802 (2.3)
  Indian                                                                       30/2113 (1.4)                41/7802 (0.5)
  Hawaiian                                                                     6/2113 (0.3)                 24/7802 (0.3)
  Ethnicity, n/N (%)                                                                                        
  Hispanic or Latino                                                           256/2132 (12.0)              511/7812 (6.5)
  Not Hispanic or Latino                                                       1876/2132 (88.0)             7301/7812 (93.5)
  Cardiac risk factors                                                                                      
  BMI (kg/m^2^)                                                                                             
  N                                                                            2117                         7790
  Median (25th, 75th)                                                          32.8 (29.0, 37.4)            28.9 (25.8, 32.9)
  Hypertension, n/N (%)                                                        1712/2144 (79.9)             4789/7858 (60.9)
  Dyslipidemia, n/N (%)                                                        1656/2144 (77.2)             5111/7858 (65.0)
  Smoker (ever/never), n/N (%)                                                 1056/2144 (49.3)             4048/7856 (51.5)
  Family history of premature CAD, n/N (%)                                     655/2140 (30.6)              2547/7830 (32.5)
  Depression, n/N (%)                                                          516/2142 (24.1)              1542/7858 (19.6)
  Sedentary lifestyle, n/N (%)                                                 1216/2142 (56.8)             3650/7840 (46.6)
  Peripheral arterial disease or cerebrovascular disease, n/N (%)              165/2144 (7.7)               387/7857 (4.9)
  Metabolic syndrome, n/N (%)                                                  1822/2144 (85.0)             1950/7858 (24.8)
  CAD risk equivalent, n/N (%)                                                 2144/2144 (100.0)            387/7858 (4.9)
  All primary presenting symptoms, n/N (%)                                                                  
  Arm or shoulder pain                                                         55/2144 (2.6)                202/7852 (2.6)
  Back pain                                                                    14/2144 (0.7)                70/7852 (0.9)
  Chest pain[a](#jah32674-note-0003){ref-type="fn"}                            1518/2144 (70.8)             5754/7852 (73.3)
  Aching/dull                                                                  368/1518 (24.2)              1471/5754 (25.6)
  Burning/pins and needles                                                     138/1518 (9.1)               532/5754 (9.2)
  Crushing/pressure/squeezing/tightness                                        746/1518 (49.1)              2854/5754 (49.6)
  Other                                                                        461/1518 (30.4)              1738/5754 (30.2)
  Fatigue or weakness                                                          58/2144 (2.7)                219/7852 (2.8)
  Neck or jaw pain                                                             14/2144 (0.7)                95/7852 (1.2)
  Palpitations                                                                 50/2144 (2.3)                186/7852 (2.4)
  Dyspnea                                                                      375/2144 (17.5)              1115/7852 (14.2)
  Other[b](#jah32674-note-0004){ref-type="fn"}                                 60/2144 (2.8)                211/7852 (2.7)
  Physician characterization of chest pain, n/N (%)                                                         
  Chest pain typicality                                                                                     
  Typical                                                                      296/2144 (13.8)              870/7858 (11.1)
  Atypical                                                                     1653/2144 (77.1)             6119/7858 (77.9)
  Noncardiac                                                                   195/2144 (9.1)               869/7858 (11.1)
  Medication use, n/N (%)                                                                                   
  Aspirin                                                                      1098/2118 (51.8)             3181/7450 (42.7)
  Statin                                                                       1291/2118 (61.0)             3097/7450 (41.6)
  Beta‐blocker                                                                 619/2118 (29.2)              1780/7450 (23.9)
  ACEi or ARB                                                                  1444/2118 (68.2)             2750/7450 (36.9)
  Diuretics                                                                    779/2118 (36.8)              1875/7450 (25.2)
  Oral hypoglycemic[c](#jah32674-note-0005){ref-type="fn"}                     1595/2144 (74.4)             0/7858 (0.0)
  Insulin[c](#jah32674-note-0005){ref-type="fn"}                               483/2144 (22.5)              0/7858 (0.0)
  ECG findings, n/N (%)                                                                                     
  ECG Q waves                                                                  126/2125 (5.9)               328/7784 (4.2)
  ECG findings that could interfere with exercise stress test interpretation   147/2126 (6.9)               439/7784 (5.6)
  LBBB                                                                         27/147 (18.4)                114/439 (26.0)
  ST depression                                                                31/147 (21.1)                94/439 (21.4)
  LVH with repolarization                                                      25/147 (17.0)                54/439 (12.3)

ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CAD, coronary artery disease; LBBB, left bundle branch block; LVH, left ventricular hypertrophy.

"Chest pain---substernal or left anterior" or "Chest pain other" are selected as primary symptoms. Multiple characterizations are possible.

Includes "Diaphoresis/sweating," "Dizziness/lightheaded," "Epigastric/abdominal pain," "Nausea/vomiting," "Syncope," and Other.

Data available only for patients with diabetes mellitus.

Chest pain was the most common presenting symptom among patients with and without diabetes mellitus (Table [1](#jah32674-tbl-0001){ref-type="table-wrap"}). There was no difference in the characteristics of the chest pain (ie, "aching/dull," "burning/pins and needles," or "crushing/pressure/squeezing/tightness") between patients with and without diabetes mellitus. Patients with diabetes mellitus were only slightly more likely to present with primary nonchest pain symptoms compared with those without diabetes mellitus (29% versus 27%), and dyspnea was more frequent (18% versus 14%). Site physicians were more likely to rate the chest pain among patients with diabetes mellitus as being typical (14% versus 11%).

Risk Scores and Coronary Disease Likelihood {#jah32674-sec-0016}
-------------------------------------------

The predicted risks of cardiovascular events were higher for patients with diabetes mellitus compared with those without diabetes mellitus for the Framingham[10](#jah32674-bib-0010){ref-type="ref"} and ASCVD[11](#jah32674-bib-0011){ref-type="ref"} risk scores (Table [2](#jah32674-tbl-0002){ref-type="table-wrap"}). The median pretest likelihood of obstructive CAD was similar for patients with diabetes mellitus as measured by the combined Diamond‐Forrester and CASS[12](#jah32674-bib-0012){ref-type="ref"} (Table [2](#jah32674-tbl-0002){ref-type="table-wrap"}). Site physicians estimated that patients with diabetes mellitus were less likely to have "very low" and "low" pretest likelihood of obstructive CAD; conversely, physicians estimated that patients with diabetes mellitus were more likely to have "intermediate," "high," and "very high" pretest likelihood of obstructive CAD.

###### 

Risk Scores and Assessment of Coronary Artery Disease Likelihood

  Characteristic                                                                                             Diabetes Mellitus (N=2144)   No Diabetes Mellitus (N=7858)
  ---------------------------------------------------------------------------------------------------------- ---------------------------- -------------------------------
  10‐y CVD risk                                                                                                                           
  Framingham risk score (2008)                                                                                                            
  N                                                                                                          2142                         7846
  Median (25th, 75th)                                                                                        28.5 (18.8, 42.8)            14.7 (9.4, 24.4)
  Low risk (\<10%), n/N (%)                                                                                  82/2142 (3.8)                2174/7846 (27.7)
  Intermediate risk (10--20%), n/N (%)                                                                       534/2142 (24.9)              3010/7846 (38.4)
  High risk (\>20%), n/N (%)                                                                                 1526/2142 (71.2)             2662/7846 (33.9)
  ASCVD (2013)                                                                                                                            
  N                                                                                                          2111                         7790
  Median (25th, 75th)                                                                                        19.8 (11.7, 32.4)            9.7 (5.5, 16.6)
  Low risk (\<7.5%), n/N (%)                                                                                 230/2111 (10.9)              2974/7790 (38.2)
  Elevated risk (\>7.5%), n/N (%)                                                                            1881/2111 (89.1)             4816/7790 (61.8)
  Pretest likelihood of obstructive CAD                                                                                                   
  Combined Diamond‐Forrester and CASS (2012)                                                                                              
  N                                                                                                          2144                         7858
  Median (25th, 75th)                                                                                        51.0 (31.0, 72.0)            51.0 (31.0, 72.0)
  Low risk (\<10%), n/N (%)                                                                                  39/2144 (1.8)                211/7858 (2.7)
  Intermediate risk (10--90%), n/N (%)                                                                       1978/2144 (92.3)             7279/7858 (92.6)
  High risk (\>90%), n/N (%)                                                                                 127/2144 (5.9)               368/7858 (4.7)
  Physician\'s estimation of likelihood of significant CAD, n/N (%)[a](#jah32674-note-0007){ref-type="fn"}                                
  Very low (\<10%)                                                                                           95/2141 (4.4)                540/7845 (6.9)
  Low (10--30%)                                                                                              510/2141 (23.8)              2610/7845 (33.3)
  Intermediate (31--70%)                                                                                     1368/2141 (63.9)             4382/7845 (55.9)
  High (71--90%)                                                                                             155/2141 (7.2)               293/7845 (3.7)
  Very high (\>90%)                                                                                          13/2141 (0.6)                20/7845 (0.3)

ASCVD indicates Atherosclerotic Cardiovascular Disease; CAD, coronary artery disease; CASS, Coronary Artery Surgery Score; CVD, cardiovascular disease.

Provider\'s assessment of the likelihood that subject has significant epicardial coronary stenosis or left main stenosis. Significant refers to ≥70% epicardial coronary stenosis or ≥50% left main stenosis.

Test Preferences {#jah32674-sec-0017}
----------------

Before randomization, providers were asked their functional test preference for each patient. Compared with patients without diabetes mellitus, for those with diabetes mellitus, exercise ECG (7% versus 11%; *P*\<0.001) and stress echocardiography (19% versus 23%; *P*\<0.001) were less frequently specified whereas stress nuclear was more likely (74% versus 66%; *P*\<0.001; Figure [1](#jah32674-fig-0001){ref-type="fig"}). Even after multivariable adjustment, patients with diabetes mellitus were more likely to have an imaging versus nonimaging test preferred (93% versus 89%; adjusted odds ratio, 1.90; *P*\<0.001; Table [3](#jah32674-tbl-0003){ref-type="table-wrap"}). Among those for whom an imaging test was preferred, stress nuclear was specified over stress echocardiography in both patients with and without diabetes mellitus, although the preference was stronger in those with diabetes mellitus (79% versus 74%; adjusted odds ratio, 1.50; *P*\<0.001; Table [3](#jah32674-tbl-0003){ref-type="table-wrap"}).

![Distribution of functional test preselection. ECHO indicates echocardiogram.](JAH3-6-e007019-g001){#jah32674-fig-0001}

###### 

Association Between Diabetes Mellitus and Prespecified Choice of Functional Test Category

  Diabetes Mellitus n/N (%)                                                                            No Diabetes Mellitus n/N (%)   Unadjusted OR (95% CI); *P* Value   Adjusted OR (95% CI); *P* Value[a](#jah32674-note-0009){ref-type="fn"}
  ---------------------------------------------------------------------------------------------------- ------------------------------ ----------------------------------- ------------------------------------------------------------------------
  Selection of imaging noninvasive test                                                                                                                                   
  1996/2144 (93)                                                                                       7020/7858 (89)                 1.91 (1.51--2.41); \<0.001          1.90 (1.50--2.41); \<0.001
  Selection of a nuclear stress test (vs stress echo) in those for whom an imaging test was selected                                                                      
  1583/1996 (79)                                                                                       5197/7020 (74)                 1.51 (1.29--1.77); \<0.001          1.50 (1.28--1.75); \<0.001

CI indicates confidence interval; OR, odds ratio.

Adjusted model controls for age, sex, and testing site (random).

Test Results {#jah32674-sec-0018}
------------

Among the 8966 patients who received their initial NIT and had interpretable results (1908 \[21%\] with diabetes mellitus and 7058 \[79%\] without diabetes mellitus), 15% of patients with diabetes mellitus had positive NIT results compared with 11% without diabetes mellitus (unadjusted odds ratio, 1.38; *P*\<0.001; adjusted odds ratio, 1.23: *P*=0.010; Table [4](#jah32674-tbl-0004){ref-type="table-wrap"}). Test positivity by testing modality is described in Figure [2](#jah32674-fig-0002){ref-type="fig"}. The distribution of abnormal test results are described in Table [S1](#jah32674-sup-0001){ref-type="supplementary-material"}. Among those patients who underwent computed tomography angiography, 15% of patients with diabetes mellitus had positive test results compared with 11% of those without diabetes mellitus. Among those who underwent stress testing, 15% of patients with diabetes mellitus had positive test results compared with 11% of those without diabetes mellitus. NIT type did not modify the relationship between diabetic status and test positivity (age‐ and sex‐adjusted interaction, *P*=0.93). Among patients with and without diabetes mellitus, the risk of adverse outcomes is greater among patients with a positive NIT result compared with those with a negative NIT result (Table [S2](#jah32674-sup-0001){ref-type="supplementary-material"}). The presence of diabetes mellitus did not modify the relationship between NIT result and death/myocardial infarction/unstable angina hospitalization (adjusted interaction *P*=0.179) or cardiovascular death/myocardial infarction (adjusted interaction *P*=0.889).

###### 

Association Between Diabetes Mellitus and Positive Initial Noninvasive Test Results

  Diabetes Mellitus n/N (%)   No Diabetes Mellitus n/N (%)   Unadjusted OR (95% CI); *P* Value   Adjusted OR (95% CI); *P* Value[a](#jah32674-note-0011){ref-type="fn"}
  --------------------------- ------------------------------ ----------------------------------- ------------------------------------------------------------------------
  289/1908 (15)               809/7058 (11)                  1.38 (1.19--1.59); \<0.001          1.38 (1.19--1.60); \<0.001

CI indicates confidence interval; OR, odds ratio.

Adjusted model controls for age, sex, and noninvasive testing modality.

![Test positivity by testing modality. CTA indicates computed tomographic angiography; Echo, echocardiogram.](JAH3-6-e007019-g002){#jah32674-fig-0002}

Predictors of a Positive NIT {#jah32674-sec-0019}
----------------------------

The clinical and demographic factors that were most predictive of a positive stress test were determined separately for patients with and without diabetes mellitus (Table [5](#jah32674-tbl-0005){ref-type="table-wrap"}). Age, sex, and chest pain characteristics were forced into both models. Among patients with diabetes mellitus, nonwhite race and Framingham Risk Score provided additional predictive information, whereas among those without diabetes mellitus, body mass index and sedentary lifestyle provided additional prognostic information. The final areas under the curve of the models were modest at 0.64 for both patients with and without diabetes mellitus.

###### 

Predictors of Test Positivity in Patients With and Without Diabetes Mellitus

                                 Models of Test Positivity[a](#jah32674-note-0013){ref-type="fn"} OR (95% CI)   
  ------------------------------ ------------------------------------------------------------------------------ -------------------
  Age                            1.02 (1.00--1.04)                                                              1.03 (1.02--1.05)
  Female                         0.74 (0.53--1.03)                                                              0.67 (0.55--0.82)
  Atypical chest pain            1.09 (0.68--1.73)                                                              1.20 (0.92--1.56)
  Typical chest pain             1.43 (0.83--2.48)                                                              1.65 (1.21--2.27)
  Race: nonwhite                 0.52 (0.36--0.75)                                                              ···
  Depression                     0.74 (0.53--1.03)                                                              ···
  Presenting symptom: dyspnea    ···                                                                            0.82 (0.66--1.02)
  Body mass index                ···                                                                            1.01 (1.00--1.03)
  Sedentary lifestyle            ···                                                                            1.17 (1.00--1.36)
  Framingham Risk Score (2008)   1.01 (1.00--1.02)                                                              1.02 (1.01--1.02)

CI indicates confidence interval; OR, odds ratio.

Final models for patients with or without diabetes mellitus selected using step‐wise selection (entry criterion: *P*\<0.1; exit criterion: *P*\>0.2) from the following candidate predictors: age; race; body mass index; hypertension; sex; metabolic syndrome; dyslipidemia; history of carotid, peripheral vascular, or cerebrovascular disease; history of heart failure; smoking (ever, never); family history of premature coronary artery disease (CAD); depression; physical activity; CAD equivalent; Framingham Risk Score (2008); Atherosclerotic Cardiovascular Disease risk prediction; Diamond‐Forrester; Combined Diamond‐Forrester and Coronary Artery Surgery Score; Diamond‐Forrester (2011); presenting symptom; and chest pain characterization. Age, sex, and chest pain characterization forced into each model.

The final model for patients with diabetes mellitus was well calibrated (Hosmer--Lemeshow Goodness of Fit *P* value, 0.345) and had good discriminatory capacity (area under the curve, 0.64 \[95% CI, 0.60--0.67\]).

The final model for patients without diabetes mellitus was well calibrated (Hosmer--Lemeshow Goodness of Fit *P* value, 0.234) and had good discriminatory capacity (area under the curve, 0.64 \[95% CI, 0.62--0.66\]).

Discussion {#jah32674-sec-0020}
==========

Cardiovascular disease is the leading cause of death among patients with diabetes mellitus; however, the impact of diabetes mellitus on the clinical presentation, diagnostic evaluation, and NIT results among stable outpatients presenting with symptoms suggestive of CAD has not been well described. In our analysis of the PROMISE trial, we identified the following major findings: (1) There were significant differences between patients with and without diabetes mellitus in comorbidities and cardiovascular risk, but clinical presentation was similar; (2) patients with and without diabetes mellitus had similar pretest likelihood of obstructive CAD, but physicians perceived patients with diabetes mellitus to have increased likelihood for obstructive CAD; (3) patients with diabetes mellitus were more likely to be referred for stress imaging tests compared with those without diabetes mellitus; (4) while patients with diabetes mellitus were more likely to have a positive NIT result, the absolute increase in risk was modest; and (5) predictors of a positive NIT result differ between patients with and without diabetes mellitus, but the ability to discriminate for a positive NIT result was moderate in both groups.

Our study demonstrated that among stable patients with symptoms suggestive of CAD, patients with diabetes mellitus have a larger burden of cardiovascular risk factors such as obesity, hypertension, and hypercholesterolemia. These results align with other cohort studies of patients with diabetes mellitus and suspected CAD undergoing stress testing.[15](#jah32674-bib-0015){ref-type="ref"}, [16](#jah32674-bib-0016){ref-type="ref"} Our study also identified that patients with diabetes mellitus had a higher likelihood of emerging risk factors, such as depression, a finding reported in other nonchest pain cohorts.[17](#jah32674-bib-0017){ref-type="ref"} The increased burden of cardiovascular risk factors is reflected in the higher cardiovascular event risk scores in patients with diabetes mellitus compared with those without diabetes mellitus (Table [2](#jah32674-tbl-0002){ref-type="table-wrap"}).

Our study is one of the largest assessments of the impact of diabetes mellitus on the presentation of low‐ to intermediate‐risk patients for symptoms suggestive of CAD. Most studies evaluating the presentation of CAD in patients with diabetes mellitus have focused on those presenting with acute coronary syndromes,[4](#jah32674-bib-0004){ref-type="ref"}, [5](#jah32674-bib-0005){ref-type="ref"}, [6](#jah32674-bib-0006){ref-type="ref"}, [7](#jah32674-bib-0007){ref-type="ref"} with some studies indicating that patients with diabetes mellitus present with atypical symptoms, whereas others do not.[6](#jah32674-bib-0006){ref-type="ref"}, [18](#jah32674-bib-0018){ref-type="ref"}, [19](#jah32674-bib-0019){ref-type="ref"} In a study of 4028 patients in Sweden presenting with their first myocardial infarction, diabetes mellitus was not an independent predictor of atypical symptoms, and there were no differences in the characteristics of symptoms between patients with and without diabetes mellitus.[19](#jah32674-bib-0019){ref-type="ref"} However, as highlighted by a previous study on sex differences in clinical presentation, symptoms in an acute setting may not necessarily be extrapolated to the stable outpatient setting.[14](#jah32674-bib-0014){ref-type="ref"} One large cohort study of 8662 ambulatory patients with suspected angina (906 with diabetes mellitus) identified that patients with diabetes mellitus had a 2‐fold increase in atypical symptoms of angina (defined as fewer than 2 of the following: constricting quality, central or left‐side location, ≤15 minutes duration, and provocation by exercise).[20](#jah32674-bib-0020){ref-type="ref"} Our analysis identified that in stable outpatients with symptoms suggestive of CAD, those with and without diabetes mellitus had very similar clinical presentations. Although patients with diabetes mellitus may have differences in clinical presentation that arise from neuropathy or comorbidities, such as obesity, this was not reflected in our study population of stable patients with symptoms suggestive of CAD.

Our study is one of the first to evaluate the impact of diabetes mellitus on the evaluation and testing of stable outpatients with symptoms suggestive of CAD. Overall, our results highlight that diabetes mellitus significantly influences the diagnostic pathway for suspected CAD. ECG exercise stress testing has been reported to have similar sensitivity and specificity among patients with and without diabetes mellitus.[21](#jah32674-bib-0021){ref-type="ref"}, [22](#jah32674-bib-0022){ref-type="ref"}, [23](#jah32674-bib-0023){ref-type="ref"} However, imaging stress tests have greater sensitivity compared with an exercise ECG test,[24](#jah32674-bib-0024){ref-type="ref"}, [25](#jah32674-bib-0025){ref-type="ref"} leading to calls to preferentially select imaging stress tests in diabetic patients,[26](#jah32674-bib-0026){ref-type="ref"} a decision which may also be influenced by physicians\' greater estimated risk of CAD in patients with diabetes mellitus (Table [3](#jah32674-tbl-0003){ref-type="table-wrap"}). Patients with diabetes mellitus may have decreased ability to exercise, as reflected by higher prevalences of peripheral arterial disease, neuropathy, and obesity, which may have influenced physician stress testing preference. Furthermore, physician perception of increased pretest likelihood of obstructive CAD among patients with diabetes mellitus may have influenced test selection. In addition, the greater likelihood of abnormalities on the baseline ECG (such as Q waves or left bundle branch block) among patients with diabetes mellitus may have also influenced physicians to choose alternative NIT modalities. In our study, physicians were more likely to select stress nuclear over stress echocardiogram. This preference was stronger in patients with diabetes mellitus compared with those without diabetes mellitus despite limited studies in this patient population to guide testing choices. For both stress echocardiography and nuclear stress imaging, limited data suggest that the sensitivity and specificity for CAD detection among patients with and without diabetes mellitus are similar.[24](#jah32674-bib-0024){ref-type="ref"}, [26](#jah32674-bib-0026){ref-type="ref"}, [27](#jah32674-bib-0027){ref-type="ref"}, [28](#jah32674-bib-0028){ref-type="ref"} To date, there has been no head‐to‐head comparison in patients with diabetes mellitus assessing the accuracy of stress nuclear versus stress echocardiography to guide NIT selection.

To our knowledge, our study has documented, for the first time, that in stable outpatients with symptoms of CAD, patients with diabetes mellitus, compared with patients without diabetes mellitus, have a greater risk of a positive NIT. Previous studies have demonstrated similar rates of test positivity between patients with and without diabetes mellitus for exercise stress ECG,[21](#jah32674-bib-0021){ref-type="ref"} stress nuclear,[24](#jah32674-bib-0024){ref-type="ref"} and conflicting results for stress echocardiography.[16](#jah32674-bib-0016){ref-type="ref"}, [28](#jah32674-bib-0028){ref-type="ref"} The differences in our results may reflect differences in patient selection (previous studies were primarily convenience samples), patient demographics, and risk‐factor profiles. Although the formal pretest scores suggest that patients with and without diabetes mellitus have similar risk of obstructive CAD, physicians perceive patients with diabetes mellitus to be at higher risk of obstructive CAD. This is supported by the observed increased risk of a positive NIT result. Given that diabetes mellitus is an established cardiovascular risk factor, further studies on the impact of diabetes mellitus on the assessment of CAD is required.

The risk factors that predicted a positive stress test among patients with and without diabetes mellitus were partially overlapping, with race, typicality of chest pain, demographics, and lifestyle variables included for both patient groups. Among patients with diabetes mellitus, body mass index and sedentary lifestyle do not add any significant predictive information. Among patients without diabetes mellitus, these 2 risk factors are significant. Other demographic and presentation characteristics, such as race and typicality of chest pain, have differential predictive value among patients with and without diabetes mellitus. These results suggest that different factors may be present in the underlying pathogenesis of CAD among patients with and without diabetes mellitus. However, the ability to discriminate for a positive test was modest in both patients with and without diabetes mellitus as reflected by the c‐statistic. These results suggest that other markers beyond baseline clinical and demographic variables should be evaluated to improve discrimination for a positive NIT among patients with and without diabetes mellitus.

Strength and Limitations {#jah32674-sec-0021}
------------------------

The PROMISE trial enrolled the largest contemporary cohort of low‐ to moderate‐risk patients presenting with stable symptoms of CAD studied to date. The pragmatic nature of the trial inclusion criteria and its community setting provided a unique opportunity to evaluate real‐world differences between patients with and without diabetes mellitus. Our study is a post‐hoc study and is subject to the inherent limitations, although analysis by diabetic status was prespecified. However, it is possible that some sites may have preferentially included or excluded diabetic patients, or those with more atypical symptoms, thereby introducing some selection bias. The presence of diabetes mellitus was established by: (1) site investigator‐reported history of diabetes mellitus; and (2) the use of antidiabetic drugs. There was no formal testing to confirm the presence of diabetes mellitus. Data on the type, duration, and degree of control of diabetes mellitus were not available. Our use of imputation of missing data for cholesterol and high‐density lipoprotein has the potential limitations of distorting the distribution of the variable with missingness as well as its association with other variables, but allowed calculation of Framingham and ASCVD risk scores. The multivariable models evaluating the association of presentation characteristics with NIT positivity were exploratory, but have been used in a previous analysis of the PROMISE trial.[14](#jah32674-bib-0014){ref-type="ref"}

Conclusions {#jah32674-sec-0022}
===========

Diabetes mellitus significantly affects clinical presentation, risk‐factor profile, stress test selection, NIT results, and predictors of a positive NIT among low‐risk patients with symptoms suggestive of coronary artery disease. However, among patients with diabetes mellitus, typical chest pain is the most common presenting complaint, and clinical presentation is similar compared with patients without diabetes mellitus. Patients with diabetes mellitus are more likely to be referred for stress imaging tests than nonimaging test and, specifically, nuclear tests. Furthermore, physicians estimate that patients with diabetes mellitus have a higher risk of obstructive CAD, and this assessment is supported by the increased risk of a positive NIT observed in our study. Given that diabetes mellitus is an established cardiovascular risk factor, additional strategies to assess for coronary artery disease, including optimal test selection and risk stratification, need to be evaluated for patients with diabetes mellitus and stable chest pain symptoms.
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